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Objectives: This randomized, double-blind, double-dummy, multicenter, controlled clinical trial com-
pared a new echinacea formulation with the neuraminidase inhibitor oseltamivir, the gold standard
treatment for inﬂuenza.
Methods: Following informed consent, 473 patients with early inﬂuenza symptoms (r48 hours) were
recruited in primary care in the Czech Republic and randomized to either 5 days of oseltamivir followed
by 5 days of placebo, or 10 days of an Echinacea purpurea-based formulation called Echinaforce Hotdrink
(A. Vogel Bioforce AG, Roggwil, Switzerland). The proportion of recovered patients (inﬂuenza symptoms
rated as absent or mild in the evening) was analyzed for noninferiority between treatment groups using
a generalized Wilcoxon test with signiﬁcance level α ¼ 0.05 (2-sided) and using a CI approach in the per-
protocol sample.
Results: Recovery from illness was comparable in the 2 treatment groups at 1.5% versus 4.1% after 1 day,
50.2% versus 48.8% after 5 days, and 90.1% versus 84.8% after 10 days of treatment with Echinaforce
Hotdrink and oseltamivir, respectively. Noninferiority was demonstrated for each day and overall (95% CI,
0.487–0.5265 by generalized Wilcoxon test). Very similar results were obtained in the group with
virologically conﬁrmed inﬂuenza virus infections and in a retrospective analysis during the peak
inﬂuenza period. The incidence of complications was lower with Echinaforce Hotdrink than with
oseltamivir (2.46% vs 6.45%; P ¼ 0.076) and fewer adverse events (particularly nausea and vomiting)
were observed with Echinaforce Hotdrink.
Conclusions: Echinaforce Hotdrink is as effective as oseltamivir in the early treatment of clinically
diagnosed and virologically conﬁrmed inﬂuenza virus infections with a reduced risk of complications and
adverse events. It appears to be an attractive treatment option, particularly suitable for self-care. Clinical
trial identiﬁer: Eudra-CT: 2010-021571-88. (Curr Ther Res Clin Exp. 2015; 77:66–72)
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Inﬂuenza presents a potential threat to human beings with
seasonal epidemics and occasional severe pandemics, following
reassortment of viral antigens. The World Health Organization
estimates a total of 25 to 50 million cases each year resulting in
150,000 hospitalizations and 30,000 to 40,000 deaths in theInc. This is an open access article u
Sc, A. Vogel Bioforce AG,United States alone, due to epidemic inﬂuenza. During pandemics
the mortality and morbidity may be much higher, putting enor-
mous pressure on basic health service provisions.1,2
Inﬂuenza illness is characterized by involvement of the lower
respiratory tract (cough) accompanied with systemic complaints,
including headache, myalgia, and fever.3,4 Acute onset of cough
and fever are good clinical predictors, associated with positive
tests for inﬂuenza virus in 79% to 88% of patients during acute
epidemics. Results depend to a large extent on detection and
sampling methods as well as the severity of epidemic.5,6 Inﬂuenza
viruses replicate predominantly in the airway epithelia, but also innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
K. Rauš et al. / Current Therapeutic Research 77 (2015) 66–72 67various other host organs and tissues leading to airway congestion,
inﬂammation, and necrosis.7 Complications are frequent and
severe complications include encephalitis, myelitis, myocarditis,
intravascular coagulation, and septic shock.8,9 Patients with under-
lying respiratory or cardiovascular disorders, children, older adults,
and immunocompromised individuals display higher rates of
severe illness and mortality.10 Overall, acute respiratory tract
infections severely inﬂuence morbidity and mortality during the
winter and inﬂuenza plays a central role in this context.11,12
Neuraminidase inhibitors are recommended for the early treat-
ment of inﬂuenza by the Centers for Disease Control and Preven-
tion, the German Gesellschaft für Virologie, and the UK National
Institute for Health and Care Excellence (NICE). The neuraminidase
inhibitors oseltamivir and zanamivir have been demonstrated to
reduce the duration and intensity of illness, but early intervention
appears critical.13,14 Success of therapy depends on the sensitivity
of causative viruses to these drugs. During the 2008–2009 winter
season most seasonal H1N1 inﬂuenza subtypes had developed
reduced sensitivity to oseltamivir. In subsequent years this resist-
ant virus type was again replaced by more sensitive strains like
H1N1pdm2009 or H3N2.15 Neuraminidase inhibitors are associ-
ated with adverse effects, including nausea, vomiting, psychiatric
effects, and renal events. Safety issues, the importance of early
administration, availability, and the potential emergence of resist-
ance compromise the broad applicability of neuraminidase inhib-
itors as recently highlighted by Jefferson et al.16
Antiviral activities are found in plants, including echinacea. A
hydroethanolic extract prepared from freshly harvested Echinacea
purpurea has demonstrated strong activity against a series
of inﬂuenza viruses (eg, H1N1, H3N2, H5N1, H7N7, and
H1N1pdm2009).17,18 The extract exhibited no potential to induce
resistance and inactivated oseltamivir-resistant H5N1 inﬂuenza
viruses. In addition to the direct inhibition of inﬂuenza viruses,
anti-inﬂammatory activities and modulation of the immune sys-
tem may contribute to echinacea’s pharmacologic spectrum.19,20
We tested efﬁcacy and safety of a newly developed preparation
of Echinacea purpurea called Echinaforce Hotdrink (A. Vogel Bio-
force AG, Roggwil Switzerland) for the treatment of acute inﬂu-
enza symptoms compared with the neuraminidase inhibitor
oseltamivir.13,14 Patients with clinically diagnosed inﬂuenza were
recruited as early as possible after symptom onset. The inclusion
criteria were matched with those for which the comparator had
demonstrated superior over placebo treatment in previous trials.
The inclusion period corresponded with the circulation period of
inﬂuenza viruses in the community. Nasal swab virus testing
further enhanced diagnostic speciﬁcity.Material and Methods
Study design
This was a randomized, double-blind, parallel, double-dummy
clinical trial conducted at 29 general practices in the Prague area of
the Czech Republic. It was conducted in accordance with the ethical
principles of the Declaration of Helsinki/Good Clinical Practice
Guideline and the applicable local regulatory requirements. The
clinical trial (Eudra-CT: 2010-021571-88) was authorized by the
competent national authorities (Štátny ústav pre kontrolu lieciv
16.11.2011) and a favorable opinion was granted by University
Hospital Hradec Kralove, Ethics Committee (1.9.2011). Directive
2001/20/EC and the related detailed guidance ENTR CT1 and CT2
were applied, as described in national legal provisions.
From November 2011 to April 2013 eligible patients were
approached and after informed, written consent was obtained,
patients were randomly allocated to receive either EchinaforceHotdrink for 10 days treatment or oseltamivir treatment for 5 days,
followed by another 5 days of treatment with oseltamivir placebo.
Rescue medication (paracetamol and dextromethorphan) was issued
for treatment of very severe symptoms. Nasal samples were taken
from participants at inclusion using midturbinate nasal swabs by the
study personnel and were placed into a tube containing transport
medium (CyMol; Copan, Brescia, Italy). The samples were kept at 41C
before shipment to the Provincial Health Services Authority British
Columbia Center for Disease Control in Vancouver, Canada, for
inﬂuenza virus detection via reverse transcription polymerase chain
reaction. Participants received a diary to record inﬂuenza symptoms
daily over the treatment period. After the treatment period patients
were requested to return to the study center for a ﬁnal visit. Returned
medication was counted and the use of rescue medication was
assessed. Blood samples were taken for analysis of hematologic and
metabolic parameters before and after treatment.
Treatment
Echinaforce Hotdrink verum contains a hydroethanolic extract
(65% v/v) of freshly harvested Echinacea purpurea. The tinctures
from the herb (drug extraction ratio 1:12) and from the roots
(drug extraction ratio 1:11) are combined at a ratio of 95% to 5%.
Two hundred forty milligrams of the above active ingredient was
concentrated to extractum spissum, which was supplemented
with 276.5 mg Sambucus fructus succus recentis (elderberry), and
excipients were added sufﬁcient to give 1 mL Echinaforce
Hotdrink. On analysis, the batch (No. 033492) was found to
contain 883 μg/100 mL dodecatetraenoic acid isobutylamide and
101 mg/100 mL rutoside. The Echinaforce Hotdrink placebo con-
tained the same excipients as verum plus colorants and ﬂavors
(Günter Aroma GmbH, Beinwil, Switzerland) for masking
(batch No. 033493). Echinafore Hotdrink verum and corresponding
placebo were ﬁlled into 200-mL dark-brown glass bottles by A.
Vogel Bioforce AG under good manufacturing practice conditions.
The comparator was manufactured by overencapsulation of
original oseltamivir capsules (Tamiﬂu 75 mg, batch No. 01130082;
Hoffmann-La Roche AG, Basel, Switzerland) using optically dense,
dark green, hard gelatine capsules, size 0 (Capsugel, Bornem,
Belgium). Corden Pharma GmbH (Plankstadt, Germany) manufac-
tured comparator capsules packed in high-density polyethylene
bottles each containing 10 capsules. The corresponding placebo
consisted of hard gelatine capsules ﬁlled with microcrystalline
cellulose and were indistinguishable from verum capsules. The
investigational products were manufactured under good manufac-
turing practice conditions and were batch released by Corden
Pharma GmbH. Paracetamol and dextromethorphan were provided
as rescue medication in form of Paralen 500 mg tablets and Stopex
30 mg tablets, respectively, sourced from Czech Republic, and were
used according to the respective manufacturers’ instructions.
Dosing
Participants in the Echinaforce Hotdrink group were instructed
to take, on the ﬁrst 3 days, 5  5 mL Echinaforce Hotdrink verum
syrup dissolved in approximately 150 mL hot water, and 3  5 mL
on the following 7 days. Accurate dosing was ensured by using a
measuring spoon, calibrated at 5 mL. In parallel, they were
instructed to take oseltamivir placebo capsules twice a day over
10 days. The oseltamivir verum group were instructed to take the
same regimen of Echinaforce Hotdrink placebo and 5 days of
oseltamivir verum capsules, followed by 5 days of oseltamivir
placebo capsules, twice daily.
Compliance was measured by weighing returned Echinaforce
Hotdrink syrup and by counting capsules and rescue medication
tablets.
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After identiﬁcation of inﬂuenza activity by Euroﬂu.org and the
Global Inﬂuenza Surveillance and Response System in the Czech
Republic during November 2011, children and adults aged 12 to 70
years with acute inﬂuenza symptoms were screened for eligibility
at 29 general practices around Prague until the end of the
inﬂuenza season in April 2013. After obtaining informed consent,
inclusion and exclusion criteria were checked. Clinical diagnosis of
inﬂuenza was based on the presence of at least 1 respiratory
symptom (eg, cough, sore throat, or nasal symptom), 1 constitu-
tional symptom (eg, headache, malaise, myalgia, sweats and/or
chills, and fatigue), and fever (Z37.81C), with symptoms not
present for more than 48 hours. A negative pregnancy test, body
weight 440 kg, good general health, and a signed informed
consent were prerequisites for inclusion.
The following exclusion criteria were applied: intake of anti-
microbial agents during the past month; inﬂuenza vaccination
during the past 12 months; suspected bacterial infection; bronchi-
tis; intake of steroid or immune-suppressive medication; preg-
nancy or breastfeeding; chronic cardiac diseases; known endocrine
disorders like diabetes mellitus; liver, kidney, and respiratory
disorders; asthma; and serious chronic diseases inﬂuencing
absorption, metabolism, and the elimination of the investigational
product. Patients with known AIDS, autoimmune disease, as well as
clinically signiﬁcant chronic disease; illness requiring hospitaliza-
tion; known allergy to plants of the Compositae family, para-
cetamol, or dextromethorphan; psychiatric disorders; neurologic
and neurodevelopment conditions; planned surgical intervention
during the trial period; alcohol or drug abuse; nicotine addiction;
and participation in another trial were excluded. Women without
effective contraception were also excluded.
In eligible patients, a physical examination was carried out,
blood pressure and heart rate were assessed, and ﬁnally blood as
well as a sample of nasal secretions were taken.
A randomization list was prepared by D.S.H. Statistical Services
(Rohrbach, Germany) using Rancode Professional 3.6 (IDV,
Gauting, Germany) with a block size of 4. The medication was
distributed to the study sites in multiples of the randomization
block. Every participant received medication on the basis of its
identiﬁcation number and in order of presentation.
Randomization codes were retained by the statistician in a sealed
envelope and a copy was kept by the investigator. Only in case of
emergency was the envelope to be opened to identify the treatment.
At the ﬁnal visit, the study patients were asked if they thought they
knew which treatment they had received. Of the patients, 16.2% in
the Echinaforce Hotdrink and 18.2% in oseltamivir group guessed
which therapy they had received, whereas 83.8% and 81.4% admitted
that they did not know. Successful blinding therefore was achieved.Sample size calculation
With 200 evaluable patients in each group, the lower limit of
the observed 1-sided 97.5% CI was expected to exceed the non-
inferiority limit of 0.42 (corresponding to a Cohen’s standardized
difference of 15%21) with 89% power if the percentage of alleviated
patients in the oseltamivir group was 80% and the Echinaforce
Hotdrink was 78%. This is based on 10,000 simulations using the
Newcombe-Wilson score method to construct the conﬁdence
interval.22 Because a generalized Wilcoxon test was used to
evaluate all primary parameters combined (Day 1, 5, and 10), a
power of at least 80% was expected for the combined hypothesis
as well. Sample size was calculated with nQuery Advisor 7.0
(lower conﬁdence limit for difference in proportions) (Statistical
Solutions Ltd, Cork, Ireland).Clinical outcomes and statistical analysis
Participants received a symptom diary to record their inﬂuenza
symptoms in the morning and evening and throughout the study
period or until recovery. Cough, nasal obstruction, sore throat,
fatigue, headache, myalgia, feverishness, malaise, sweats, and/or
chills were rated as 0 ¼ not present, 1 ¼ mild, 2 ¼ moderate, or
3 ¼ severe. Axillary body temperature was measured by electronic
thermometer in degrees Celsius, sleeping disorders for the pre-
ceding night and ability to return to regular daily activities were
scored yes/no, and intake of study medication as well as rescue
and comedication and cotherapies was recorded. Occurrence of
complications (eg, pneumonia, sinusitis, bronchitis, or other) was
recorded at the close-out visit as was the need for intermed visits/
contacts, hospitalization, and for antibiotic treatment. Patients and
physicians rated tolerability as well as efﬁcacy on a subjective basis
using a Likert scale where 1 ¼ very good, 2 ¼ good, 3 ¼ moderate,
and 4 ¼ poor. Finally, patients gave their opinions whether they
would take the same medication again.
The primary end point of the study was the cumulative propor-
tion of patients with inﬂuenza symptoms alleviated (recovered)
after 1 day, 5 days, and 10 days of treatment. Recovery was deﬁned
as the ﬁrst day when cough, nasal obstruction, sore throat, fatigue,
headache, myalgia, and feverishness were rated as absent or mild in
the evening. The analysis of noninferiority between treatments
based on the per-protocol cohort, deﬁned as those who fulﬁlled
inclusion and exclusion criteria, took at least 80% of study medi-
cation, and did not take unauthorized concomitant medication.
Secondary variables included evaluation of further inﬂuenza
symptoms, number of days with sleep disturbance, time point of
return to normal activity, evolution of body temperature, use of
rescue medication, and additional health care contacts. The propor-
tion of patients experiencing respiratory respective gastrointestinal
complications that required premature treatment stop was analyzed.
Statistical analysis used standard noninferiority methods.
The combined hypothesis (inferiority of Echinaforce Hotdrink to
oseltamivir on Days 1, 5, and 10 in terms of the primary end point)
at the level of α ¼ 0.05 was ﬁrst tested. If this hypothesis was
rejected single hypotheses were to be tested. These additional
hypotheses were inferiority on single Days 1, 5, and 10 for
Hypothesis 1, Hypothesis 2, and Hypothesis 3, and at a level of
α/2 and α/3 with Bonferroni correction. Noninferiority for the
individual measurements was considered to have been demon-
strated when the lower conﬁdence limit was above 0.42 in the
Mann-Whitney statistics.
To detect adverse events (AEs) patients were asked, “Did you
experience any unusual or unexpected symptom since your last
visit, apart from the symptoms recorded in the diary?" Changes in
concomitant diseases and medications as well as laboratory
parameters were also taken into account before judgment of AE
causality. Lowest level terms were chosen, which were translated
into preferred terms before classiﬁcation into system organ class
using MedDRA Dictionary (version 13.1) (McLean, Virginia, USA).
Blood samples were analyzed for erythrocytes, hematocrit, hemo-
globin, leucocytes, Mean corpuscular hemoglobin (MCH), mean
corpuscular hemoglobin concentration (MCHC), mean corpuscular
volume (MCV), thrombocytes, aspartate aminotransferase, choles-
terol, creatinine, total bilirubin, and gamma-glutamyl transferase.Results
In total, 473 patients, all Caucasian with early acute inﬂuenza
symptoms, were screened and enrolled in the study from Novem-
ber 22, 2011, until April 29, 2013. Of the 237 and 236 patients
allocated to the 2 treatment groups (Echinaforce Hotdrink and
Table 1
Patient characteristics in the analysis collective (per protocol).
Characteristic* Echinaforce
Hotdrink†
(n ¼ 203)
Oseltamivir
(n ¼ 217)
P value
(Wilcoxon)
Age (y) 37.7 (13.9) 36.7 (13.1) 4 0.05
Body weight (kg) 77.7 (16.9) 74.9 (15.5) 4 0.05
Body height (cm) 173.3 (9.9) 173.2 (9.3) 4 0.05
Body mass index 25.8 (4.8) 24.9 (4.1) 4 0.05
K. Rauš et al. / Current Therapeutic Research 77 (2015) 66–72 69oselatmivir, respectively), 6 were lost to follow-up because they
did not attend the close-out appointment, and 1 patient did not
receive the allocated intervention. Another 18 and 10 patients had
major protocol violations, and compliance in 11 and 6 cases was
o80% in the Echinaforce Hotdrink and comparator groups,
respectively. These patients were excluded from the efﬁcacy
analysis. One patient took nonpermitted medication. Finally, a
total of 203 and 217 patients were included in the per-protocol
group for analysis of efﬁcacy (Figure 1).Sex
Female 94 (46.3) 116 (53.5) 4 0.05
Male 109 (53.7) 101 (46.5)
n Values for age, body weight, and body mass index are presented as mean
(SD). Values for sex are presented as n (%).
† A. Vogel Bioforce AG, Roggwil, Switzerland.Demographic data and other baseline characteristics
Patients in the 2 treatment groups were comparable with
regard to age, body weight, body height, body mass index, and
sex distribution (Table 1). Most participants (n ¼ 464) were adults
more than 18 years in age; mean age was 37 years. Nine children
and adolescents aged between 12 and 17 years were included in
the study. Physical baseline values, including heart rate and blood
pressure, were similar in the treatment groups. Obtained preg-
nancy tests were all negative and nasal secretions were collected
from all but 1 patient (in the Echinaforce Hotdrink group).
The most prominent respiratory symptom was cough, present
in 87.2% and 85.3% of patients at inclusion. Congruent with the
case deﬁnition and study indication, inﬂuenza lead symptoms,
cough, myalgia, headache, and feverishness, were prominent, and
the typical common cold symptom of sore throat less so (Table 2).
There was a small but almost signiﬁcant difference in the mean
axillary temperature of patients at baseline: in the Echinaforce
Hotdrink group it was 38.31C (7 0.81C) and 38.21C (7 0.81C) in
the comparator group (P ¼ 0.065). At inclusion, headache and
cough showed a trend to greater severity in the Echinaforce
Hotdrink group (P o 0.1). The mean (SD) duration of exposure
to medication for Echinaforce Hotdrink was 10.1 (1.2) days and 9.9
(1.8) days in the comparator group.Assessed for
(n=47
Lost to follow-up (had no time for v2)
(n=3)
Allocation
Analysi
(pp collect
Randomize
Follow-U
Analysed (n=203)
Violating in-/exclusion criteria (n=18)
Compliance < 80% (n=11)
Non-permitted medication (n=1)
Excluded from analysis (n=30)
Allocated to intervention (n=237)
Received allocated intervention (n=236)
Did not receive allocated intervention
(allocation error) (n=1)
Figure 1. Patient ﬂCompliance and blinding
Among patients, 91.7% from the Echinaforce Hotdrink group
and 90.5% of those in the comparator group took at least 80% of the
planned study medication. Less than 80% of the study medication
was taken by 8.3% and 9.5% of Echinaforce Hotdrink and compa-
rator patients, respectively. For 3 patients in each group this was
due to alleviation of symptoms before Day 5, and for 5 patients
(2.2%) with Echinaforce Hotdrink and 13 patients (5.6%) with
oseltamivir failure to take all of the medication was due to
occurrence of an AE. Blinding was effective, with 83.8% and 91.4%
not knowing whether they received Echinaforce Hotdrink or
oseltamivir verum in the respective groups.
Efﬁcacy analysis
Primary and secondary variables of efﬁcacy are displayed for
the per-protocol group. Unless otherwise stated, the data corre-
spond to the intention to treat group. Figure 2 shows the eligibility
3)
Excluded (n=0)
s
ive)
d (n=473)
Lost to follow-up (had no time for v2) (n=3)
p
Analysed (n=217)
Excluded from analysis (n=16)
Violating in-/exclusion criteria (n=10)
Compliance < 80% (n=6)
Allocated to intervention (n=236)
Received allocated intervention (n=236)
Did not receive allocated intervention (n=0)
ow diagram.
Table 2
Baseline inﬂuenza symptoms. Percentage of patients rating individual symptoms as
“moderate” or “severe.”
Symptom Echinaforce
Hotdrink*
(n ¼ 203)
Oseltamivir
(n ¼ 217)
P value
(Mantel-
Haenszel χ2)
Cough 82.82 76.15 0.017
Fatigue 80.21 75.64 0.682
Myalgia 70.31 58.88 0.181
Feverishness 69.27 69.03 0.651
Headache 67.19 54.31 0.061
Nasal obstruction 66.67 59.39 0.131
Sweats and chills 59.16 61.42 0.576
Sore throat 44.79 48.22 0.414
Malaise 20.84 20.82 0.742
n A. Vogel Bioforce AG, Roggwil, Switzerland.
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recovery rates were very similar for the 2 treatment groups.
Alleviation of symptoms after 1, 5, and 10 days of treatment was
observed in 1.5% and 4.1%; 50.2% and 48.8%; and 90.1% and 84.8% at
10 days in patients treated with Echinaforce Hotdrink and oselta-
mivir, respectively (as demonstrated in Table 3). Noninferiority of
Echinaforce Hotdrink to oseltamivir was demonstrated for each
day (Mann-Whitney statistics) as well as in the generalized
analysis over all days of measurement (generalized Wilcoxon test,
P[xoY] ¼ 0.5068; 95% CI, 0.4871–0.5265). The percentage of
treatment failures after 10 days showed a nonstatistically signiﬁ-
cant trend favoring Echinaforce Hotdrink: 15.2% in the oseltamivir
group versus 9.9% with Echinaforce Hotdrink (P 4 0.05).
The above analysis concerned the total of patients with clin-
ically diagnosed inﬂuenza illness. Next we tested for the primary
variable in the subgroup with conﬁrmed inﬂuenza virus in nasal
samples at inclusion. Positive samples were obtained from a total
of 41 patients (24.4% with inﬂuenza type A [H3 strain], 41.5%
nontypeable inﬂuenza A, 31.7% inﬂuenza B viruses, and 2.4% of
samples with coinfection of inﬂuenza A and B). The rates of
recovery of patients with conﬁrmed inﬂuenza virus infection were
very similar to those in clinically diagnosed inﬂuenza patients
(primary parameter). Alleviation of symptoms after 1, 5, and 10
days of treatment was observed in 0% and 0%; 45.0% and 42.9%;
and 95.0% and 76.2% of patients treated with Echinaforce Hotdrink
and oseltamivir, respectively. Again, inferiority of Echinaforce0
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Figure 2. Proportion of patients with alleviated inﬂuenza symptoms in the per-
protocol group (n ¼ 420). A total of 9.9% did not respond to Echinaforce Hotdrink
(A. Vogel Bioforce AG, Roggwil, Switzerland) treatment in comparison to 15.2% who
did not respond to oseltamivir treatment until Day 10.Hotdrink compared with oseltamivir was not detected in the
generalized analysis or for the individual days of measurement.
In contrast, at Day 10 Echinaforce Hotdrink was signiﬁcantly
superior in the 1-sided Wilcoxon test (P ¼ 0.0365).
In another sensitivity analysis we compared outcomes during
the period of peak inﬂuenza activity according to Euroﬂu and Global
Inﬂuenza Surveillance and Response System data (calendar week 5–
16 [2012] and calendar week 50 [2012]–calendar week 17 [2013]).
Subgroups comprised a sample size of 347 and 367 patients, which
represented a good part of the overall population, indicating
selective recruiting during inﬂuenza season. In this group the
recovery curves matched well with those of the whole group and
again noninferiority could be demonstrated (data not shown).
In the overall study group the individual symptoms resolved
quickly and there was no noticeable difference between the
treatment groups. The inﬂuenza lead symptoms cough, headache,
and myalgia showed a marked reduction, which was slightly more
marked in the Echinaforce Hotdrink group without reaching
statistical signiﬁcance (P 4 0.05). Body temperature normalized
to afebrile within 2 days of treatment in both groups (median,
2 days; P ¼ 0.193). Figure 3 shows the evolution of axillary
temperature in the 2 treatment groups. No difference between
groups was observed in terms of return to normal daily activities
and nights with sleeping disturbance (data not shown).
Complications are frequently seen in patients with inﬂuenza,
and are a major reason for hospitalization and mortality. In
previous studies, oseltamivir was shown to reduce incidence of
lower respiratory tract complications from 10.3% to 4.6% (P o
0.001).23 A similar, relatively low incidence of complications was
recorded in this study. In the oseltamivir group a total of 14 (6.5%)
complications occurred. Nine (4.6%) concerned respiratory com-
plications, including pneumonia (n ¼ 2), sinusitis (n ¼ 4),
bronchitis (n ¼ 2), and rhinopharyngitis (n ¼ 1). In the Echina-
force Hotdrink group the incidence of complications was lower at
2.5% and this difference approaches statistical signiﬁcance (χ2 test
P ¼ 0.079) (Figure 4). Antibiotic use was very low in both
treatment groups at 1.8% and 2.0% in the oseltamivir and Echina-
force Hotdrink groups, respectively (P ¼ 1.00).
No hospitalizations were reported during the investigational
period in either treatment group. Patients had the option to
contact the physician during the treatment period for any reason.
About 7% of patients from the Echinaforce Hotdrink group and
about 10% from the oseltamivir group requested an additional
health care contact between the inclusion and close-out visits. The
use of rescue medication was counted at the close-out visit, and no
statistical difference was detected. The Echinaforce Hotdrink group
took, over a mean of 3.1 and 3.5 days, a mean total of 7.1 and 7.6 g
paracetamol and dextromethorphan, respectively. The comparator
group took, over a mean of 3.1 and 3.8 days, a mean total of 6.3 and
8.1 g of the same medications (P ¼ 0.17 to 0.86). At the end of the
study, 85.2% and 86.6% of patients, respectively, were able to
return to normal daily activities. There was no statistically signiﬁ-
cant difference between groups.
Finally, physicians and participants made a personal judgment
of the efﬁcacy of the treatment at the end of the study. One
hundred eighty-six investigators (91.6%) judged Echinaforce Hot-
drink as “good” or “very good” compared with 198 (91.2%) for the
comparator. There was no statistically signiﬁcant difference
between groups (per-protocol population). Patient assessment
was similarly positive with 87.2% and 86.2%, respectively, rating
treatment efﬁcacy as “good” or “very good.”
Safety analysis
Overall, 31 AEs were reported by 26 patients (11.4%) in the
Echinaforce Hotdrink group (n ¼ 229), and 44 AEs were reported
Table 3
Mann-Whitney statistics (MWS) and conﬁdence limits of the noninferiority analysis are given for individual treatment days and the global test, applying alpha levels of 0.017
and 0.05, respectively (per protocol analysis, N ¼ 420).
Criterion Alleviation after 1 day Alleviation after 5 days Alleviation after 10 days Global test (Days 1, 5, and 10)
MWS 0.4867 0.5070 0.5268 0.5068
Conﬁdence limits 98.3% CI, (0.4676–0.5057) 98.3% CI, (0.4487–0.5652) 98.3% CI, (0.4884–0.5651) 95% CI, (0.4871–0.5265)
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events were assessed to be related to the study medication—4
events from 4 patients (1.7%) treated with Echinaforce Hotdrink
and 6 events from 5 patients (2.2%) treated with oseltamivir. Five
(2.2%) and 12 (5.2%) patients stopped Echinaforce Hotdrink and
comparator treatment because of AEs. The higher incidence of AEs
in the oseltamivir group was largely due to gastrointestinal
disorders like nausea and vomiting. Nausea and vomiting were
5 times more frequent with oseltamivir (15 reports) than with
Echinaforce Hotdrink (3 reports) and in 9 cases led to treatment
cessation. No serious AEs such as encephalitis, myelitis, myocardi-
tis, or septic shocks were reported. No clinically relevant changes
in metabolic or hematologic laboratory parameters (erythrocytes,
leucocytes, thrombocytes, hemoglobin, hematocrit, MCV, MCH,
MCHC, creatinine, cholesterol, total bilirubin, aspartate amino-
transferase, and gamma-glutamyl transferase) were observed
between the inclusion and close-out visits.
Two hundred nineteen patients (95.6%) from the Echinaforce
Hotdrink group and 214 patients (93%) from the oseltamivir group
judged the tolerability of the treatment as “good” or “very good.”
There was no statistically signiﬁcant difference between groups.Discussion
The clinical efﬁcacy and safety of a novel formulation of
Echinacea purpurea, Echinaforce Hotdrink, was compared with
oseltamivir in patients with early symptoms of inﬂuenza. The
study design and conditions matched with large clinical trials
showing superiority of oseltamivir over placebo treatment. An
early inclusion of patients (mean 25.1 hours after symptom onset)
was achieved by recruiting patients in primary care. Under these
conditions, noninferiority of Echinaforce Hotdrink to oseltamivir
was demonstrated in terms of recovery from illness.
The speciﬁcity and robustness of effects was further examined,
ﬁrst in virologically conﬁrmed inﬂuenza virus infections and
second by focusing on infections during peak inﬂuenza activity.
The detection efﬁciency of inﬂuenza viruses was relatively low but
comparable with reports from the Canadian Respiratory Virus
Detection Surveillance System. They found a consistent35
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Figure 3. Evolution of mean (SD) body temperature (˚C) during the study period.synchronization of negative with positive tests for inﬂuenza (but
not with other respiratory viruses), which was associated with a
high number of false negative results using a Poisson regression
model.24 The predominance of inﬂuenza viruses ﬁnally can be
concluded from the predominance of inﬂuenza cardinal symptoms
over the negative predictor sore throat in the included sample of
our study. The therapeutic effects of Echinaforce Hotdrink appear
robust and consistent in varying scenarios; for example, clinically
diagnosed inﬂuenza, during inﬂuenza peak activity, as well as in
virologically conﬁrmed inﬂuenza virus infections.
The results of this double-blind randomized controlled trial are
consistent with in vitro results obtained from the studied echina-
cea extract (Echinaforce). A variety of inﬂuenza A and B virus
types, including the strains observed in this study (H3N2, H5N1,
H1N1pdm09, and inﬂuenza B), are sensitive to the extract at low
concentrations of 0.1 to 50 μg/mL.17,18 Likewise, echinaforce
signiﬁcantly prevented membranous virus infections, including
inﬂuenza, during 4 months of application of echinacea extract in
comparison to placebo treatment.25 Emergence of drug resistance
was not observed even after serial passaging of H1N1 viruses
in vitro.17
Despite slightly higher baseline values of pyrexia, cough, head-
ache, and myalgia in the Echinaforce Hotdrink group, equalization
of symptoms between groups was achieved after 2 to 3 days. Fever
resolved within 2 days of treatment and cardinal inﬂuenza
symptoms were effectively treated with both therapies. At the
end of the treatment period, more patients had recovered in the
Echinaforce Hotdrink group, although the difference was border-
line signiﬁcant.
Previous studies of oseltamivir of comparable design have
yielded results comparable to ours. Complications are frequently
observed in patients with inﬂuenza and are a major reason for
hospitalization and mortality. In comparable clinical trials, com-
plications were observed in 5.3% to 18.5% in placebo groups,
depending on the general health.23 In these studies oseltamivir
reduced incidence of lower respiratory tract complications from
10.3% to 4.6% on average (P o 0.001).
Similar incidences were detected in our study: with oseltami-
vir, a total of 6.5% patients developed any complication
(4.6% affecting the respiratory tract). With Echinaforce Hotdrink
treatment complications, were very low at 2.5% and the difference0
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Figure 4. Occurrence of complications accompanying use of Echinaforce Hotdrink
(A. Vogel Bioforce AG, Roggwil, Switzerland) and oseltamivir treatment.
K. Rauš et al. / Current Therapeutic Research 77 (2015) 66–7272to the comparator was almost statistically signiﬁcant. There were
no hospitalizations in either treatment group.
In comparison with the existing literature, both therapies
performed well and were similarly effective in the treatment of
inﬂuenza illness and its complications. Likewise, a reduced need
for antibiotics was observed; this has been up to 19% in placebo-
treated patients in similar trials.23 In our study, in both treatment
groups the percentage of patients requiring antibiotics was low
(2% and 1.8%) and not signiﬁcantly different between groups.
The presence of oseltamivir-resistant inﬂuenza virus strains (ie,
seasonal inﬂuenza A H1N1) might undermine the assay sensitivity
of our study because of reduced efﬁcacy of the comparator with
these strains. The World Health Organization-collaborating Centre
for Reference and Research on Inﬂuenza, which reviewed the
susceptibility of recent human and avian inﬂuenza virus types,
found the H1N1pdm09, H3N2, and inﬂuenza B strains to be fully
sensitive to neuraminidase inhibitors in general, and oseltamivir in
particular, during this time frame.26
Gastrointestinal disorders have been reported for oseltamivir
treatment with an incidence of 10.7%. These include nausea,
vomiting, and diarrhea (summary of product characteristics, Tami-
ﬂu, Hoffmann-La Roche AG, Basel, Switzerland). In our study,
gastrointestinal complaints in 9 patients lead to cessation of therapy
in the oseltamivir group, which in 5 cases prevented recovery from
inﬂuenza illness. No such event occurred with Echinaforce Hot-
drink, and safety was clearly in favor of the latter therapy.
In view of the comparable beneﬁts (recovery from illness),
possible advantages (lack of induction of drug resistance and
complications), and the lower incidence of AEs, treatment of
inﬂuenza with Echinaforce Hotdrink overall outperformed treat-
ment with oseltamivir in the studied patient cohort. Further
studies are warranted to show the extent to which our results
are applicable to patients with concomitant diseases and at-risk
populations, which were not studied here.Conclusions
Neuraminidase inhibitors are the main current therapeutic
option for the treatment of inﬂuenza and are recommended by
authoritative bodies in several countries. Risk of drug resistance,
safety issues, and limited availability challenge their usefulness for
the early inﬂuenza therapy in reality. Echinaforce Hotdrink has
been demonstrated to be an attractive therapy for acute inﬂuenza
treatment with a better safety and a comparable efﬁcacy proﬁle to
the neuraminidase inhibitor oseltamivir. Its availability as an over-
the-counter medicine allows for a very early treatment start,
which is central for treatment success with any intervention.
Further studies are warranted.Acknowledgments
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